, Volume 7, Issue 4, pp 335–345 | Cite as

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  • Yaning Wang
  • David Fei
  • Martin Vanderlaan
  • An SongEmail author


Bevacizumab (Avastin™, Genentech) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in both physiological and pathological conditions. It has been recently approved by the US FDA as a first-line therapy for widespread metastatic colorectal cancer. This report is a detailed biological characterization of bevacizumab in a variety of in vitro models. It is shown that bevacizumab potently neutralizes VEGF and blocks its signal transduction through both the VEGFR-1 and VEGFR-2 receptors, as demonstrated by the inhibition of VEGF-induced cell proliferation, survival, permeability, nitric oxide production, as well as migration and tissue factor production. Although bevacizumab retains the ability to bind to human Fcγ receptors and complement protein C1q, it does not demonstrate cell or complement-mediated cytotoxicity in either VEGF producing or targeting cells. Thus the mechanism of anti-tumor activity of bevacizumab is most likely due to its anti-angiogenesis effect through binding and neutralization of secreted VEGF.


angiogenesis bevacizumab (Avastin™) endothelial cells (ECs) human umbilical vein endothelial cell (HUVEC) tissue factor (TF) vascular endothelial growth factor (VEGF) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Risau, W, Lemmon, V 1988Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesisDev Biol125441450CrossRefPubMedGoogle Scholar
  2. 2.
    Risau, W, Sariola, H, Zerwes, HG,  et al. 1988Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodiesDevelopment102471478PubMedGoogle Scholar
  3. 3.
    Ferrara, N 2001Role of vascular endothelial growth factor in regulation of physiological angiogenesisAm J Physiol Cell Physiol280C1358C1366PubMedGoogle Scholar
  4. 4.
    Plate, KH, Warnke, PC 1997Vascular endothelial growth factorJ Neuro-Oncol35363370CrossRefGoogle Scholar
  5. 5.
    Zhou, Z, Wang, J, Cao, R,  et al. 2004Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient miceCancer Res6446994702PubMedGoogle Scholar
  6. 6.
    Taylor, P 2002VEGF and imaging of vessels in rheumatoid arthritisArthritis Res4S99S107CrossRefPubMedGoogle Scholar
  7. 7.
    Paleolog, E 2002Angiogenesis in rheumatoid arthritisArthritis Res4S81S90CrossRefPubMedGoogle Scholar
  8. 8.
    Witmer, AN, Vrensen, GFJM, Van Noorden, CJF, Schlingemann, RO 2003Vascular endothelial growth factors and angiogenesis in eye diseaseProg Retinal Eye Res22129CrossRefGoogle Scholar
  9. 9.
    Ferrara, N, Henzel, WJ 1989Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun161851858CrossRefPubMedGoogle Scholar
  10. 10.
    Carmeliet, P, Ng, YS, Nuyens, D,  et al. 1999Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188Nat Med5495502CrossRefPubMedGoogle Scholar
  11. 11.
    Yancopoulos, GD, Davis, S, Gale, Nw,  et al. 2000Vascular-specific growth factors and blood vessel formationNature407242248CrossRefPubMedGoogle Scholar
  12. 12.
    Ferrara, N, Gerber, HP, LeCouter, J 2003The biology of VEGF and its receptorsNat Med9669676PubMedGoogle Scholar
  13. 13.
    Ferrara, N, Alitalo, K 1999Clinical applications of angiogenic growth factors and their inhibitorsNat Med513591364CrossRefPubMedGoogle Scholar
  14. 14.
    Ferrara, N 2002Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implicationsSemin Oncol291014CrossRefGoogle Scholar
  15. 15.
    Folkman, J 2002Role of angiogenesis in tumor growth and metastasisSemin Oncol291518CrossRefGoogle Scholar
  16. 16.
    Rugo, HS 2004Bevacizumab in the treatment of breast cancer: Rationale and current dataOncologist94349CrossRefGoogle Scholar
  17. 17.
    Longo, R, Sarmiento, R, Fanelli, M,  et al. 2001Anti-angiogenic therapy: Rationale, challenges and clinical studiesAngiogenesis5237256CrossRefGoogle Scholar
  18. 18.
    Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies (CE) (July/August). Ann Pharmacother 2004: aph.1D470Google Scholar
  19. 19.
    Ferrara, N, Hillan, KJ, Gerber, H-P, Novotny, W 2004Discovery and development of Bevacizumab, an anti-vegf antibody for treating cancerNature Rev Drug Discov3391400CrossRefGoogle Scholar
  20. 20.
    Boocock, CA, Charnock-Jones, DS, Sharkey, AM,  et al. 1995Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinomaJ Natl Cancer Inst87506516PubMedGoogle Scholar
  21. 21.
    Pietsch, TVM, Wolf, HK, Deimling, A,  et al. 1997Expression and distribution of vascular endothelial growth factor protein in human brain tumorsActa Neuropathol (Berl).93109117CrossRefGoogle Scholar
  22. 22.
    Kim, KJLB, Houck, K, Winer, J, Ferrara, N 1992The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodiesGrowth Factors75364PubMedGoogle Scholar
  23. 23.
    Kim KJLB, Winer J, Armanini M. et al.(1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 841–4Google Scholar
  24. 24.
    Presta, LG, Chen, H, O’Connor, SJ,  et al. 1997Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersCancer Res5745934599PubMedGoogle Scholar
  25. 25.
    Borgstrom, PBM, Hillan, KJ, Sriramarao, P, Ferrara, N 1998Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivoProstate35110CrossRefPubMedGoogle Scholar
  26. 26.
    Borgstrom, PHK, Sriramarao, P, Ferrara, N 1996Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopyCancer Res5640324039PubMedGoogle Scholar
  27. 27.
    Soh, EY, Eigelberger, MS, Kim, KJ,  et al. 2000Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivoSurgery12810591066CrossRefPubMedGoogle Scholar
  28. 28.
    Yuan, F, Chen, Y, Dellian, M 1996Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibodyPNAS931476514770CrossRefPubMedGoogle Scholar
  29. 29.
    Ryan, AMED, Hagler, KE, Bruner, Rh,  et al. 1999Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibodyToxicol Pathol277886PubMedGoogle Scholar
  30. 30.
    Hurwitz, H, Fehrenbacher, L, Novotny, W,  et al. 2004Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerN Engl J Med35023352342CrossRefPubMedGoogle Scholar
  31. 31.
    Ferrara, N, Davis-Smyth, T 1997The biology of vascular endothelial growth factorEndocr Rev18425CrossRefPubMedGoogle Scholar
  32. 32.
    Keyt, BA, Nguyen, HV, Berleau, LT,  et al. 1996Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptorsJ Biol Chem271563846CrossRefPubMedGoogle Scholar
  33. 33.
    Ansar Ahmed, S, Gogal, J, Robert, M, Walsh, JE 1994A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to [3H]thymidine incorporation assayJ Immunol Meth17021124CrossRefGoogle Scholar
  34. 34.
    Breslin, JW, Pappas, PJ, Cerveira, JJ,  et al. 2003VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxideAm J Physiol Heart Circ Physiol284H92H100PubMedGoogle Scholar
  35. 35.
    Friedl, J, Puhlmann, M, Bartlett, DL,  et al. 2002Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: Relationship between the procoagulant and permeability effects of TNFBlood10013341339PubMedGoogle Scholar
  36. 36.
    Kroll, J, Waltenberger, J 1999A novel function of VEGF receptor-2 (KDR): Rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cellsBiochem Biophys Res Commun265636639CrossRefPubMedGoogle Scholar
  37. 37.
    Papapetropoulos, A, Garcia-Cardena, G, Madri, JA, Sessa, WC 1997Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cellsJ Clin Invest10031313139PubMedGoogle Scholar
  38. 38.
    Shields, RL, Namenuk, AK, Hong, K,  et al. 2001High resolution mapping of the binding site on human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma RJ Biol Chem27665916604CrossRefPubMedGoogle Scholar
  39. 39.
    Idusogie, EE, Presta, LG, Gazzano-Santoro, H,  et al. 2000Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 FcJ Immunol164417884PubMedGoogle Scholar
  40. 40.
    Lal, BK, Varma, S, Pappas, PJ.,  et al. 2001VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathwaysMicrovas Res62252262CrossRefGoogle Scholar
  41. 41.
    Barleon, B, Sozzani, S, Zhou, D.,  et al. 1996Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1Blood8733363343PubMedGoogle Scholar
  42. 42.
    Clauss, M, Pipp, F, Issbrucker, K.,  et al. 2003Dissection of monocyte and endothelial activities by using VEGF-receptor specific ligandsAdv Exp Med Biol5227582PubMedGoogle Scholar
  43. 43.
    Pipp, F, Heil, M, Issbrucker, K.,  et al. 2003VEGFR-1-selective VEGF homologue PlGF Is arteriogenic: Evidence for a monocyte-mediated mechanismCirc Res92378385CrossRefPubMedGoogle Scholar
  44. 44.
    Sawano, A, Iwai, S, Sakurai, Y.,  et al. 2001Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humansBlood97785791CrossRefPubMedGoogle Scholar
  45. 45.
    Ben-Av, P, Crofford, LJ, Wilder, RL, Hla, T. 1995Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesisFEBS Lett3728387CrossRefPubMedGoogle Scholar
  46. 46.
    Cohen, T, Nahari, D, Cerem, LW.,  et al. 1996Interleukin 6 Induces the expression of vascular endothelial growth factorJ Biol Chem271736741CrossRefPubMedGoogle Scholar
  47. 47.
    Frank, S, Hübner, G, Breier, G.,  et al. 1995Regulation of vascular endothelial growth factor expression in cultured keratinocytesJ Biol Chem2701260712613Google Scholar
  48. 48.
    Levy, AP, Levy, NS, Wegner, S, Goldberg, MA. 1995Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxiaJ Biol Chem2701333313340CrossRefPubMedGoogle Scholar
  49. 49.
    Liu, Y, Cox, SR, Morita, T, Kourembanas, S. 1995Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: Identification of a 5’ enhancerCirc Res77638643PubMedGoogle Scholar
  50. 50.
    Warren, RS, Yuan, H, Matli, MR.,  et al. 1996Induction of vascular endothelial growth factor by insulin-like growth factor in colorectal carcinomaJ Biol Chem2712948329488CrossRefPubMedGoogle Scholar
  51. 51.
    Wang, H, Keiser, JA. 1998Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells : Role of flt-1Circ Res83832840PubMedGoogle Scholar
  52. 52.
    Lamoreaux, WJ, Fitzgerald, ME, Reiner, A.,  et al. 1998Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitroMicrovasc Res552942CrossRefPubMedGoogle Scholar
  53. 53.
    Prewett, M, Huber, J, Li, Y.,  et al. 1999Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumorsCancer Res5952095218PubMedGoogle Scholar
  54. 54.
    Willett CG, Boucher Y, di Tomaso E. et al.(2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 10(2): 145–147Google Scholar
  55. 55.
    Zeng, H, Dvorak, HF, Mukhopadhyay, D. 2001Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent PathwaysJ Biol Chem2762696926979CrossRefPubMedGoogle Scholar
  56. 56.
    Clauss, M, Weich, H, Breier, G.,  et al. 1996The vascular endothelial growth factor receptor Flt-1 mediates biological activities. implications for a functional role of placenta growth factor in monocyte activation and chemotaxisJ Biol Chem2711762917634CrossRefPubMedGoogle Scholar
  57. 57.
    Kendall, RL, Wang, G, Disalvo, J, Thomas, KA. 1994Specificity of vascular endothelial cell growth factor receptor ligand binding domainsBiochem Biophys Res Commun201326330CrossRefPubMedGoogle Scholar
  58. 58.
    Waltenberger, J, Claesson-Welsh, L, Siegbahn, A.,  et al. 1994Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factorJ Biol Chem2692698826995PubMedGoogle Scholar
  59. 59.
    Poon, RT-P, Lau, CP-Y, Ho, JW-Y.,  et al. 2003Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinomaClin Cancer Res953395345PubMedGoogle Scholar
  60. 60.
    Altomare, DF, Rotelli, MT, Memeo, V.,  et al. 2003Expression of tissue factor and vascular endothelial growth factor in colorectal carcinomaTumori8956PubMedGoogle Scholar
  61. 61.
    Creasey AARK. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 2001; 29(7).Google Scholar
  62. 62.
    Versteeg, HH, Peppelenbosch, MP, Spek, CA. 2003Tissue factor signal transduction in angiogenesisCarcinogenesis2410091013CrossRefPubMedGoogle Scholar
  63. 63.
    Kuenen, BC, Levi, M, Meijers, JC.,  et al. 2002Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patientsArterioscler Thromb Vasc Biol2215001505CrossRefPubMedGoogle Scholar
  64. 64.
    Belting, M, Dorrell, MI, Sandgren, S.,  et al. 2004Regulation of angiogenesis by tissue factor cytoplasmic domain signalingNat Med10502509CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Yaning Wang
    • 1
  • David Fei
    • 1
    • 2
  • Martin Vanderlaan
    • 1
  • An Song
    • 1
    Email author
  1. 1.Department of BioAnalytical Research & DevelopmentGenentechSan FranciscoUSA
  2. 2.Analytical Development, BioPharmaceuticalsChiron CorporationEmeryvilleUSA

Personalised recommendations